Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female
Interventions: DRUG: Abemaciclib 50 MG; 150mg 1-0-1 per os
Sponsor: West German Study Group
Collaborators: Eli Lilly and Company|Genomic Health®, Inc.